Biodexa (NASDAQ: BDXA) Teams with Syngene for MTX240 Clinical Trial Manufacturing

April 2, 2026

Key Developments Biodexa (NASDAQ: BDXA) has officially announced a strategic partnership with Syngene to produce Good Manufacturing Practice (GMP) clinical trial supplies of MTX240. The collaboration aims to advance the production and supply logistics for MTX240, a promising therapeutic candidate undergoing clinical trials. This partnership solidifies Biodexa’s commitment to accelerating the clinical development phase for MTX240 by ensuring high-quality and compliant manufacturing capabilities from Syngene. The agreement marks a significant…

Read More >>